SUNNYVALE, Calif., Sept. 27, 2016 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that data from a
prospective, 21 center study showed 97 percent of low- and
intermediate-risk prostate cancer patients had excellent cancer
control five years after receiving stereotactic body radiation
therapy (SBRT) administered with the CyberKnife® System. The
treatment was extremely well-tolerated; serious side effects were
uncommon (less than two percent) after more than five years of
follow-up. The study was presented during an oral session yesterday
at the American Society for Radiation Oncology (ASTRO) 58th Annual
Meeting and was one of 15 to be selected out of thousands of
abstracts for presentation during an ASTRO press conference,
scheduled for today.
SBRT is a treatment process necessitating an extremely high
degree of precision. It offers a much shorter course of treatment
for prostate cancer patients than conventional radiation and is
noninvasive (no conventional surgery involved). SBRT is
cost-effective for healthcare providers and payers, and also
increases patient satisfaction by reducing discomfort and
scheduling inconvenience versus conventional radiation
treatments.
"For men with newly diagnosed prostate cancer, this study
changes the game. SBRT provided better cancer control with few side
effects, and required only 5 short treatments, without the need for
surgery." said Robert M. Meier, MD,
medical director of the Swedish Cancer Institute at Northwest
Hospital in Seattle, Washington
and lead investigator of the study. "The CyberKnife System's
real-time image guidance, non-coplanar beam delivery, and
sub-millimeter accuracy enabled clinicians across multiple centers
to achieve consistent, excellent dose control, with reduced
toxicities compared to other radiotherapies."
The study titled, "Five-Year Outcomes from a Multi-Center Trial
of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk
Prostate Cancer," is the first large, multi-center clinical trial
with long-term follow-up and good quality assurance to evaluate the
use of SBRT in prostate cancer delivered by the CyberKnife System.
It demonstrated that:
- Five-year recurrence-free survival rates were almost identical
for low- and intermediate-risk patients;
- In low-risk prostate cancer patients the five-year cancer
control rate (97.3 percent) was superior to historical external
beam radiation therapy control rates (93 percent);
- Dose-escalated prostate CyberKnife SBRT can be safely
administered across multiple institutions, reinforcing the
feasibility of the treatment methodology;
- Toxicity rates compare favorably to other radiotherapies, based
on results from other studies.
The prostate gland can move unpredictably throughout the course
of treatment because of normal patient bodily functions. This makes
it vitally important to be able to track, detect and correct for
all types of motion. Unlike any other radiation treatment, the
CyberKnife® System continually tracks and automatically corrects
the beam for movement of the prostate in real-time throughout the
entire treatment session. With this automatic motion-tracking and
adjustment, the CyberKnife® System's accuracy is sub-millimeter --
its pinpoint precision is within the thickness of a dime, enhancing
clinicians' ability to treat effectively while preserving healthy
tissue.
"This most recent research demonstrates clearly why the
CyberKnife System has become the radiation therapy system of choice
for many clinicians and their patients when evaluating treatment
options for prostate cancer," said Fabienne Hirigoyenberry-Lanson,
PhD, vice president global clinical development, at Accuray. "The
System is uniquely positioned to play an important role in
delivering on the far-reaching priorities of health systems
worldwide seeking to improve patient outcomes and reduce
costs."
About the Study
The study was designed to assess whether dose-escalated
stereotactic body radiation therapy (SBRT) could be effectively and
safely administered across multiple community, regional and
academic institutions. Additionally, the study evaluated whether,
in low-risk patients, dose escalation would improve five-year
disease-free survival rates compared to historic controls. Study
participants included 309 evaluable patients, 172 low-risk and 137
intermediate-risk. All patients were treated with a non-coplanar
robotic SBRT platform, the CyberKnife System, using real-time
tracking of implanted fiducials.
Important Safety Information
For Important Safety Information please refer to
http://www.accuray.com/safety-statement-radiation-treatment
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes, adoption of Accuray's
technologies and Accuray's leadership position in radiation
oncology innovation and technologies. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including but not
limited to the risks detailed from time to time under the heading
"Risk Factors" in the company's report on Form 10-K, filed on
August 28, 2015, the company's
reports on Form 10-Q, filed on November 5,
2015 and February 1, 2016 and
April 29, 2016, and the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future
events. The company assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly,
investors should not put undue reliance on any forward-looking
statements.
Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Sherry Feldberg
MSLGROUP
+1 (781) 684-6680
Sherry.Feldberg@mslgroup.com
Logo -
http://photos.prnewswire.com/prnh/20160108/320376LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/prospective-multi-institutional-study-shows-five-treatments-with-the-cyberknife-system-provide-excellent-disease-control-for-prostate-cancer-patients-300334169.html
SOURCE Accuray Incorporated